Safety, Pharmacokinetics and Pharmacodynamics of DS-1040, in Combination with Thrombectomy, in Japanese Patients with Acute Ischemic Stroke

BACKGROUND AND OBJECTIVES: DS-1040 is a novel inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor that may have therapeutic potential in thromboembolic diseases, such as acute ischemic stroke (AIS) or pulmonary embolism. We undertook a Phase I clinical trial to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakai, Nobuyuki, Takeuchi, Masataka, Imamura, Hirotoshi, Shimamura, Norihito, Yoshimura, Shinichi, Naito, Hiromichi, Kimura, Naoto, Masuo, Osamu, Hirotsune, Nobuyuki, Morita, Kenichi, Toyoda, Kazunori, Yamagami, Hiroshi, Ishihara, Hideyuki, Nakatsu, Takafumi, Miyoshi, Naoki, Suda, Miharu, Fujimoto, Shigeru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844171/
https://www.ncbi.nlm.nih.gov/pubmed/35061236
http://dx.doi.org/10.1007/s40261-021-01112-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844171/
https://www.ncbi.nlm.nih.gov/pubmed/35061236
http://dx.doi.org/10.1007/s40261-021-01112-8

Ejemplares similares